Trial Profile

A Phase I clinical study to characterize the safety, tolerability, pharmacokinetics, and effects of IM156 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IM 156 (Primary)
Indications Idiopathic pulmonary fibrosis
Focus Adverse reactions
Sponsors ImmunoMet Therapeutics

Most Recent Events

19 Oct 2022 According to an ImmunoMet Therapeutics media release, IM156 was well-tolerated in healthy volunteers.
26 Jul 2021 According to an ImmunoMet Therapeutics media release, dosing has been completed in the study.
03 May 2021 Status changed from planning to recruiting, according to an ImmunoMet Therapeutics media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com